2019 Q2 Form 10-Q Financial Statement

#000135657619000025 Filed on August 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $104.7M $99.54M
YoY Change 5.18% 31.32%
Cost Of Revenue $4.044M $3.683M
YoY Change 9.8% -5.56%
Gross Profit $100.7M $95.86M
YoY Change 5.0% 33.13%
Gross Profit Margin 96.14% 96.3%
Selling, General & Admin $39.78M $40.10M
YoY Change -0.8% 14.24%
% of Gross Profit 39.52% 41.83%
Research & Development $16.97M $20.04M
YoY Change -15.31% 85.54%
% of Gross Profit 16.86% 20.9%
Depreciation & Amortization $1.700M $1.800M
YoY Change -5.56% 28.57%
% of Gross Profit 1.69% 1.88%
Operating Expenses $56.75M $60.14M
YoY Change -5.63% 31.01%
Operating Profit $42.60M $35.72M
YoY Change 19.26% 36.86%
Interest Expense $5.389M -$700.0K
YoY Change -869.86% -216.67%
% of Operating Profit 12.65% -1.96%
Other Income/Expense, Net $148.0K -$1.864M
YoY Change -107.94% 832.0%
Pretax Income $42.75M $33.86M
YoY Change 26.26% 28.24%
Income Tax $10.02M $3.119M
% Of Pretax Income 23.44% 9.21%
Net Earnings $32.73M $30.74M
YoY Change 6.47% 76.65%
Net Earnings / Revenue 31.26% 30.88%
Basic Earnings Per Share $0.62 $0.59
Diluted Earnings Per Share $0.61 $0.57
COMMON SHARES
Basic Shares Outstanding 52.39M shares 51.92M shares
Diluted Shares Outstanding 53.91M shares 54.20M shares

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $258.6M $174.4M
YoY Change 48.28% 87.53%
Cash & Equivalents $87.34M $35.21M
Short-Term Investments $171.2M $139.2M
Other Short-Term Assets $21.80M $14.60M
YoY Change 49.32% 210.64%
Inventory $26.02M $20.70M
Prepaid Expenses
Receivables $84.56M $74.80M
Other Receivables $0.00 $0.00
Total Short-Term Assets $390.9M $284.5M
YoY Change 37.4% 71.9%
LONG-TERM ASSETS
Property, Plant & Equipment $4.028M $4.900M
YoY Change -17.8% 6.52%
Goodwill
YoY Change
Intangibles $28.79M
YoY Change
Long-Term Investments $593.8M $503.3M
YoY Change 17.98% 381.17%
Other Assets $581.0K $26.30M
YoY Change -97.79% -38.41%
Total Long-Term Assets $672.8M $568.3M
YoY Change 18.38% 214.15%
TOTAL ASSETS
Total Short-Term Assets $390.9M $284.5M
Total Long-Term Assets $672.8M $568.3M
Total Assets $1.064B $852.8M
YoY Change 24.73% 146.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.081M $2.900M
YoY Change 40.72% -61.84%
Accrued Expenses $134.5M $99.30M
YoY Change 35.45% 39.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $144.0M $103.9M
YoY Change 38.57% 21.52%
LONG-TERM LIABILITIES
Long-Term Debt $337.2M $321.9M
YoY Change 4.75% 21360.0%
Other Long-Term Liabilities $10.96M $36.50M
YoY Change -69.99% 21.67%
Total Long-Term Liabilities $10.96M $358.4M
YoY Change -96.94% 1037.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $144.0M $103.9M
Total Long-Term Liabilities $10.96M $358.4M
Total Liabilities $540.8M $462.3M
YoY Change 16.97% 295.13%
SHAREHOLDERS EQUITY
Retained Earnings $137.6M
YoY Change
Common Stock $52.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $522.9M $390.5M
YoY Change
Total Liabilities & Shareholders Equity $1.064B $852.8M
YoY Change 24.73% 146.19%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income $32.73M $30.74M
YoY Change 6.47% 76.65%
Depreciation, Depletion And Amortization $1.700M $1.800M
YoY Change -5.56% 28.57%
Cash From Operating Activities $28.70M $6.600M
YoY Change 334.85% -74.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$300.0K
YoY Change -100.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$65.80M -$421.8M
YoY Change -84.4% 1600.81%
Cash From Investing Activities -$65.80M -$422.1M
YoY Change -84.41% 1568.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.600M 6.700M
YoY Change -76.12% 318.75%
NET CHANGE
Cash From Operating Activities 28.70M 6.600M
Cash From Investing Activities -65.80M -422.1M
Cash From Financing Activities 1.600M 6.700M
Net Change In Cash -35.50M -408.8M
YoY Change -91.32% -18681.82%
FREE CASH FLOW
Cash From Operating Activities $28.70M $6.600M
Capital Expenditures $0.00 -$300.0K
Free Cash Flow $28.70M $6.900M
YoY Change 315.94% -73.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0001356576
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
130000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52316583 shares
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52449036 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52316583 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52449036 shares
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 USD
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35518
dei Entity Registrant Name
EntityRegistrantName
SUPERNUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-2590184
dei Entity Address Address Line1
EntityAddressAddressLine1
1550 East Gude Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Rockville
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20850
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
838-2500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52449036 shares
dei Trading Symbol
TradingSymbol
SUPN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87344000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192248000 USD
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
171222000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
163770000 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
84564000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
102922000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
26024000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
25659000 USD
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21757000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8888000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
390911000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
493487000 USD
CY2019Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
593754000 USD
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
418798000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4028000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4095000 USD
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28787000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31368000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19639000 USD
CY2019Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
25975000 USD
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
581000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
380000 USD
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
29683000 USD
CY2019Q2 us-gaap Assets
Assets
1063675000 USD
CY2018Q4 us-gaap Assets
Assets
977811000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4081000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3195000 USD
CY2019Q2 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
95934000 USD
CY2018Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107063000 USD
CY2019Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
38614000 USD
CY2018Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
36535000 USD
CY2019Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2674000 USD
CY2018Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
12377000 USD
CY2019Q2 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
2668000 USD
CY2018Q4 supn Non Recourse Debt Sale Of Future Royalties Current
NonRecourseDebtSaleOfFutureRoyaltiesCurrent
2183000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
143971000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
161353000 USD
CY2019Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
337210000 USD
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
329462000 USD
CY2019Q2 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
21100000 USD
CY2018Q4 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
22575000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27535000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10955000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11398000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
540771000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
524788000 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
379369000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
369637000 USD
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5924000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3158000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
137559000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
86492000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
522904000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
453023000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1063675000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
977811000 USD
CY2019Q2 us-gaap Revenues
Revenues
104695000 USD
CY2018Q2 us-gaap Revenues
Revenues
99538000 USD
us-gaap Revenues
Revenues
190169000 USD
us-gaap Revenues
Revenues
189967000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4044000 USD
CY2018Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3683000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7728000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6961000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20038000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32364000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38946000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16970000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41083000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
35720000 USD
us-gaap Costs And Expenses
CostsAndExpenses
122143000 USD
us-gaap Costs And Expenses
CostsAndExpenses
122853000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
42598000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
68026000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
67114000 USD
CY2018Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40097000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
82051000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
76946000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
62097000 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
63818000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
148000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1864000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1041000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2076000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
42746000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
33856000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
66985000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
65038000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10019000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3119000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15918000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7949000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
30737000 USD
us-gaap Net Income Loss
NetIncomeLoss
51067000 USD
us-gaap Net Income Loss
NetIncomeLoss
57089000 USD
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.10
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.06
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52385590 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51919894 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52361149 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51729243 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53912977 shares
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54203308 shares
us-gaap Net Income Loss
NetIncomeLoss
57089000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4497000 USD
CY2018Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1828000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53947834 shares
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
30737000 USD
us-gaap Net Income Loss
NetIncomeLoss
51067000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1184000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
9082000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3372000 USD
CY2018Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
5462000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54021941 shares
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4497000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1828000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9082000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3372000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37224000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28909000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
60149000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
53717000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
453023000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3287000 USD
CY2019Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
783000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18340000 USD
CY2019Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4585000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
480018000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4022000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1377000 USD
CY2019Q2 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
263000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4497000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
522904000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
267480000 USD
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
269802000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2635000 USD
CY2018Q1 supn Stock Issued During Period Value Stock Options And Warrants Exercised
StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
2858000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
56215000 USD
CY2018Q1 supn Purchases Of Convertible Note Hedges Net Of Tax
PurchasesOfConvertibleNoteHedgesNetOfTax
-70137000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
65688000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
26352000 USD
CY2018Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1544000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
351869000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3068000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7748000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4307000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
30737000 USD
CY2018Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1828000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3355000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3487000 USD
supn Amortization Of Operating Lease Assets
AmortizationOfOperatingLeaseAssets
1230000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
390492000 USD
us-gaap Profit Loss
ProfitLoss
51067000 USD
us-gaap Profit Loss
ProfitLoss
57089000 USD
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
93000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1625000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
1835000 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
2851000 USD
supn Interest Expense Non Recourse Royalty Liability
InterestExpenseNonRecourseRoyaltyLiability
1905000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
3368000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
2780000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7309000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5703000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
861000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-395000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-18439000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7776000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
365000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4376000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
3581000 USD
supn Increase Decrease In Prepaid Deferred Expense And Other Current Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherCurrentAssets
8060000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
140000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
342000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
886000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3838000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
-11129000 USD
supn Increase Decrease In Accrued Product Returns And Rebates
IncreaseDecreaseInAccruedProductReturnsAndRebates
1701000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1307000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2964000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-9703000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-15938000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-755000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1873000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61680000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
33689000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
264926000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
491655000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
96165000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
65688000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
19466000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
245000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
557000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
764976000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
582568000 USD
CY2018Q4 supn Accrued Product Costs Current
AccruedProductCostsCurrent
38000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
401000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-169007000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-473147000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
402500000 USD
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0 USD
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
10435000 USD
supn Purchases Of Convertible Note Hedge
PurchasesOfConvertibleNoteHedge
0 USD
supn Purchases Of Convertible Note Hedge
PurchasesOfConvertibleNoteHedge
92897000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2423000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9503000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2423000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
374359000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-104904000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65099000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192248000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100304000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87344000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35205000 USD
us-gaap Interest Paid Net
InterestPaidNet
1258000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
24795000 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
29279000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
2704000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
2707000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
280000 USD
supn Non Cash Capitalized Cost Of Intangible Assets
NonCashCapitalizedCostOfIntangibleAssets
480000 USD
supn Lease Asset And Tenant Receivable Obtained For Operating Lease
LeaseAssetAndTenantReceivableObtainedForOperatingLease
31727000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supernus Pharmaceuticals, Inc. (the Company) was incorporated in Delaware and commenced operations in 2005. The Company is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> products: Oxtellar XR for the treatment of epilepsy and Trokendi XR for the prophylaxis of migraine headache and treatment of epilepsy. The Company has several proprietary product candidates in clinical development that address the CNS market.</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company launched Oxtellar XR and Trokendi XR for the treatment of epilepsy in 2013, launched Trokendi XR for the prophylaxis of migraine headache in adolescents and adults in April 2017 and launched Oxtellar XR with an expanded indication to include monotherapy for partial seizures in January 2019.</span></div>
supn Number Of Proprietary Commercial Products
NumberOfProprietaryCommercialProducts
2 product
CY2018Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
36535000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company bases its estimates on: historical experience; various forecasts; information received from its service providers; and other assumptions that the Company believes are reasonable under the circumstances. Actual results could differ materially from the Company’s estimates. The Company evaluates the methodologies employed in its estimates on an ongoing basis.</span></div>
CY2019Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 USD
supn Sales Return Period Prior To Expiration
SalesReturnPeriodPriorToExpiration
P6M
supn Sales Return Period
SalesReturnPeriod
P12M
supn Number Of Commercial Products
NumberOfCommercialProducts
2 product
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2175000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4561000 USD
CY2019Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
38614000 USD
supn Threshold Limit For Medical Claim
ThresholdLimitForMedicalClaim
150000 USD
CY2019Q2 supn Self Insurance Liability
SelfInsuranceLiability
500000 USD
us-gaap Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
<div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Advertising Expense</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Advertising expense includes costs of promotional materials and activities, such as marketing materials, marketing programs and speaker programs. The costs of the Company’s advertising efforts are expensed as incurred.</span></div><div style="line-height:120%;padding-top:13px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurred approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>21.2</span></span><span style="font-family:inherit;font-size:10pt;"> million in advertising costs for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$11.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in advertising costs for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. These expenses are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative </span><span style="font-family:inherit;font-size:10pt;">in the condensed consolidated statements of earnings.</span></div>
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
757206000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
586726000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7966000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
55000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
196000 USD
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4213000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
171222000 USD
CY2019Q2 supn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
192488000 USD
CY2019Q2 supn Available For Sale Securities Debt Maturities Two Years Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesTwoYearsThroughThreeYearsFairValue
200597000 USD
CY2019Q2 supn Available For Sale Securities Debt Maturities Three Years Through Four Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThreeYearsThroughFourYearsFairValue
200669000 USD
CY2019Q2 supn Available For Sale Securities Debt Maturities Thereafter Fair Value
AvailableForSaleSecuritiesDebtMaturitiesThereafterFairValue
0 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
764976000 USD
CY2019Q2 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
4953000 USD
CY2018Q4 us-gaap Inventory Work In Process And Raw Materials Net Of Reserves
InventoryWorkInProcessAndRawMaterialsNetOfReserves
5742000 USD
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7527000 USD
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
7275000 USD
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13544000 USD
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
12642000 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
26024000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
25659000 USD
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15990000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15314000 USD
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11962000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11219000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4028000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4095000 USD
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000 USD
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000 USD
CY2019Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15968000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
13356000 USD
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28787000 USD
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31368000 USD
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2600000 USD
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2600000 USD
CY2019Q2 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
17398000 USD
CY2018Q4 supn Accrued Clinical Trial And Clinical Supply Costs Current
AccruedClinicalTrialAndClinicalSupplyCostsCurrent
14034000 USD
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11339000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13546000 USD
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3703000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3706000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3357000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q2 us-gaap Interest Payable Current
InterestPayableCurrent
629000 USD
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
650000 USD
CY2019Q2 supn Accrued Product Costs Current
AccruedProductCostsCurrent
13000 USD
CY2019Q2 supn Accrued Rebates
AccruedRebates
74362000 USD
CY2018Q4 supn Accrued Rebates
AccruedRebates
85003000 USD
CY2019Q2 supn Accrued Product Returns
AccruedProductReturns
21572000 USD
CY2018Q4 supn Accrued Product Returns
AccruedProductReturns
22060000 USD
CY2019Q2 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
95934000 USD
CY2018Q4 supn Accrued Product Returns And Rebates
AccruedProductReturnsAndRebates
107063000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2019Q2 us-gaap Interest Income Other
InterestIncomeOther
5453000 USD
CY2018Q2 us-gaap Interest Income Other
InterestIncomeOther
3664000 USD
us-gaap Interest Income Other
InterestIncomeOther
10134000 USD
us-gaap Interest Income Other
InterestIncomeOther
4870000 USD
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4169000 USD
CY2018Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4324000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
8879000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5041000 USD
CY2019Q2 us-gaap Interest Expense Other
InterestExpenseOther
1136000 USD
CY2018Q2 us-gaap Interest Expense Other
InterestExpenseOther
1204000 USD
us-gaap Interest Expense Other
InterestExpenseOther
2296000 USD
us-gaap Interest Expense Other
InterestExpenseOther
1905000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
148000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1864000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1041000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2076000 USD
CY2019Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3900000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7700000 USD
CY2018Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3700000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4300000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4022000 USD
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3068000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7309000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5703000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.9063
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1527387 shares
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
32727000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
30737000 USD
us-gaap Net Income Loss
NetIncomeLoss
51067000 USD
us-gaap Net Income Loss
NetIncomeLoss
57089000 USD
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52385590 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51919894 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52361149 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51729243 shares
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2283414 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1586685 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2292698 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53912977 shares
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54203308 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53947834 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54021941 shares
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.10
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.06
CY2019Q2 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
12000000.0 USD
CY2018Q4 supn Allowance For Expected Sales Deductions
AllowanceForExpectedSalesDeductions
11500000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10019000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3119000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15918000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7949000 USD
CY2019Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2340
CY2018Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0920
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.2380
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1220
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19639000 USD
CY2019Q2 supn Tenant Receivable Leases Additional Allowance For Tenant And Capital Improvement
TenantReceivableLeasesAdditionalAllowanceForTenantAndCapitalImprovement
9720000 USD
CY2019Q2 supn Lessee Operating Lease Assets
LesseeOperatingLeaseAssets
29359000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3357000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27535000 USD
CY2019Q2 supn Lessee Operating Lease Liabilities
LesseeOperatingLeaseLiabilities
30892000 USD
CY2019Q2 supn Operating Lease Fixed Lease Cost
OperatingLeaseFixedLeaseCost
987000 USD
supn Operating Lease Fixed Lease Cost
OperatingLeaseFixedLeaseCost
2019000 USD
CY2019Q2 supn Operating Lease Variable Lease Cost
OperatingLeaseVariableLeaseCost
518000 USD
supn Operating Lease Variable Lease Cost
OperatingLeaseVariableLeaseCost
983000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1505000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
3002000 USD
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y4M6D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0436
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1704000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3054000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2687000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2526000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2537000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
29371000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
41879000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10987000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
30892000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3600000 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2700000 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2700000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
3400000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2287000 USD
CY2018Q4 supn Operating Leases Future Minimum Payments Thereafter Due
OperatingLeasesFutureMinimumPaymentsThereafterDue
1840000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7527000 USD
CY2019Q2 us-gaap Revenues
Revenues
104695000 USD
CY2018Q2 us-gaap Revenues
Revenues
99538000 USD
us-gaap Revenues
Revenues
190169000 USD
us-gaap Revenues
Revenues
189967000 USD
CY2019Q2 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
1800000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
3400000 USD
CY2018Q2 supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
1500000 USD
supn Revenue From Royalty Agreement
RevenueFromRoyaltyAgreement
2800000 USD
CY2014Q3 supn Non Recourse Debt Sale Of Future Royalties Noncurrent
NonRecourseDebtSaleOfFutureRoyaltiesNoncurrent
30000000.0 USD

Files In Submission

Name View Source Status
0001356576-19-000025-index-headers.html Edgar Link pending
0001356576-19-000025-index.html Edgar Link pending
0001356576-19-000025.txt Edgar Link pending
0001356576-19-000025-xbrl.zip Edgar Link pending
currentportfolio2q19.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
supn-20190630.xsd Edgar Link pending
supn-20190630x10q.htm Edgar Link pending
supn-20190630x10qxex311.htm Edgar Link pending
supn-20190630x10qxex312.htm Edgar Link pending
supn-20190630x10qxex321.htm Edgar Link pending
supn-20190630x10qxex322.htm Edgar Link pending
supn-20190630x10q_htm.xml Edgar Link completed
supn-20190630_cal.xml Edgar Link unprocessable
supn-20190630_def.xml Edgar Link unprocessable
supn-20190630_lab.xml Edgar Link unprocessable
supn-20190630_pre.xml Edgar Link unprocessable